ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO640

Incidence Rates of Primary Focal Segmental Glomerulosclerosis (FSGS) Within a Diverse Adult Southern California Population, 2010-2021

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Munis, Mercedes A., Kaiser Permanente Southern California, Pasadena, California, United States
  • Chen, Qiaoling, Kaiser Permanente Southern California, Pasadena, California, United States
  • Hill, T. Matthew, Otsuka Pharmaceutical Development and Commercialization Inc, Princeton, New Jersey, United States
  • Harrison, Teresa N., Kaiser Permanente Southern California, Pasadena, California, United States
  • Bhattacharjee, Sandipan, Otsuka Pharmaceutical Development and Commercialization Inc, Princeton, New Jersey, United States
  • Schachter, Asher Daniel, Visterra Inc, Waltham, Massachusetts, United States
  • Fernandes, Ancilla, Otsuka Pharmaceutical Development and Commercialization Inc, Princeton, New Jersey, United States
  • Zhuo, Min, Visterra Inc, Waltham, Massachusetts, United States
  • Sim, John J., Kaiser Permanente Southern California, Pasadena, California, United States
Background

FSGS is a leading cause of end-stage kidney disease. However, little epidemiologic data exist exploring the specific FSGS subtypes that increases the importance of understanding this rare disease and subsequent management strategies. The goal of this study was to estimate the incidence of FSGS and primary FSGS among a large diverse population in the United States.

Methods

A retrospective cohort study within Kaiser Permanente Southern California was performed among patients (age ≥18yrs) with renal biopsy-proven FSGS between 2010-2021. Presumed primary FSGS consisted of biopsies with FSGS as the principal diagnosis. Manual chart reviews were then performed to confirm primary FSGS with extensive foot process effacement (FPE) of ≥80%. Patient demographics were assessed during the 1 year prior to date of biopsy (index date). Annual incidence rates (per 100,000 person-years) were calculated after adjusting to 2020 US census.

Results

Among 7,115,249 unique persons, we identified 3,839 patients with biopsy-proven FSGS. Of 1,509 presumed primary FSGS, 640 (42.4%) were confirmed primary FSGS (mean age [SD] 55.5 years [17.9], 56.4% male, 35.8% Hispanic/Latino, 28.8% White, 17.8% Asian/Pacific Islander, 15.9% Black). The adjusted annual incidence rates of primary FSGS ranged from 1.3 – 2.4 per 100,000 person-years (Table 1). The highest mean primary FSGS incidence rates per 100,000 person-years were among Black (3.4), Asian (2.7), and Pacific Islander (2.8) patients (Table 2).

Conclusion

Among a racially/ethnically diverse population, primary FSGS accounted for 16.7% of all biopsy-proven FSGS. Our findings suggest that primary FSGS remains a rare disease but varies across race/ethnicity. Proper identification of primary FSGS in patients may help facilitate tailoring therapeutic options.

Funding

  • Commercial Support – Otsuka Pharmaceutical Development & Commercialization, Inc.